请输入您要查询的百科知识：

　

词条 BioLineRx
释义

  1. Operations

      Pipeline    Business model  

  2. Corporate history

      Management  

  3. See also

  4. References

  5. External links

{{Infobox company
| name = BioLineRx Ltd.
| logo = BioLineRx.png
| caption =
| type = Public
| traded_as = {{NASDAQ|BLRX}}
{{TASE|BLRX}}
| fate =
| predecessor =
| successor =
| foundation = {{Start date and age|2003}}
| founder =
| defunct =
| location_city = Modiin
| location_country = Israel
| area_served =
| key_people = Philip Serlin (CEO)
| industry = Biotechnology
| products =
| services = Drug development
| revenue =
| operating_income =
| net_income =
| assets =
| equity =
| owners = Novartis (12.8%, 2014)
| num_employees =
| parent =
| divisions =
| subsid =
| homepage = {{URL|www.biolinerx.com}}
| footnotes = [1][2]
| intl =
}}

BioLineRx ({{Lang-he|ביוליין אר אקס}}), or BioLine, is a publicly traded drug development company that seeks to discover compounds for disease treatment and develop them into commercializable drugs. Headquartered in Israel, its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange.

Operations

BioLineRx is a drug development company that seeks to discover compounds with potential to treat a variety of diseases, including cancer, schizophrenia and cardiac deterioration. When promising compounds are discovered, BioLine leads them through preclinical trials and engages other companies to advance the compounds' development into commercializable drugs.[2] The company entered into its first major commercialization agreement in 2009 when it partnered with Ikaria Holdings Inc. to develop its BL-1040 compound.[3] In 2010 BioLine entered into a commercialization agreement with Cypress Bioscience Inc. for development of its BL-1020 compound. The agreement with Cypress was canceled in 2011 when the company was taken over by Ramius LLC.[4]

Pipeline

Below is a partial list of drug compounds in various stages of development by BioLineRx. Unless indicated otherwise, they have not obtained regulatory approval in relation to the diseases cited.

  • BL-1010 – orally available neuropathic pain[5]
  • BL-1020 – orally available GABA-enhanced antipsychotic for treatment of schizophrenia[6]
  • BL-1021 – orally available small molecule for treatment of neuropathic pain[7]
  • BL-1040 – liquid polymer injected into patients suffering from acute myocardial infarction, invented by Smadar Cohen of Ben-Gurion University[8][9]
  • BL-1230 - a potent and selective cannabinoid receptor type 2 (CB2R) agonist intended as a novel treatment for Dry Eye Syndrome (DES) [10]
  • BL-5010 – cream treatment for seborrheic keratosis skin lesions[11]
  • BL-7040 – orally available anti-inflammatory drug invented by Hermona Soreq of the Hebrew University of Jerusalem[12]
  • BL-8020 – orally administered treatment for Hepatitis C, developed by Professor Philippe Halfon, Co-Founder and President of Genoscience.
  • BL-8030 – second-generation NS3 protease inhibitor for oral treatment of Hepatitis C, invented by Philippe Halfon[13]

Business model

{{See also|Bench to bedside|Proof of concept}}

BioLine's business model consists of three stages. In the first stage, called the bench stage, the potential drug candidate is evaluated "from both scientific and marketing perspectives." In the second stage, called the bedside stage, BioLine accompanies the drug through early clinical trials. In the third stage, the partner stage, BioLine enters into strategic partnership with a pharmaceutical company to see the drug through its advanced clinical trials and bring it to the market.[14]

Corporate history

BioLineRx was established in 2003 as a joint venture of Teva, Hadasit Bio-Holdings, the Jerusalem Development Authority, Yehuda Zisapel, and other investors.[15] It executed an initial public offering on the Tel Aviv Stock Exchange in February 2007, raising 211 million NIS ($50 million) – the TASE's largest biotech IPO until that time.[16][17] In August 2011 BioLine's ADRs began trading on the NASDAQ Capital Market.[18][19] In January 2012, BioLineRx announced a deal with Genoscience, a French pharmaceutical company to jointly develop and market the BL-8020 compound, as a treatment for Hepatitis C.[20] At the end of 2014, Novartis acquired a 12.8% stake in the company as a strategic move to gain access to Israeli-sourced drug candidates.[21]

Management

Morris Laster, Downstate Medical Center (M.D.) and SUNY Albany (B.Sc.) alumnus, was CEO of BioLineRx until 2009. He was replaced by Kinneret Savitsky, alumnus of Tel Aviv University (Master's and Ph.D.) and the Hebrew University of Jerusalem (B.Sc.), early in 2010.[22] Savitsky was replaced as CEO by BioLine COO Philip Serlin on October 10, 2016.[23]

See also

  • Translational medicine
  • TA BlueTech Index
  • List of Israeli companies quoted on the Nasdaq

References

1. ^{{cite web|title=BLRX Profile: BioLineRx Ltd. Stock|url=https://finance.yahoo.com/q/pr?s=BLRX+Profile|work=Yahoo! Finance|accessdate=28 November 2011|year=2011}}
2. ^{{cite news |last=Brinn |first=David |title=BioLineRx—Israel's biotech supermarket |url=http://www.israel21c.org/health/biolinerx-israel-s-biotech-supermarket |accessdate=28 November 2011 |work=ISRAEL21c |date=3 June 2007 |deadurl=yes |archivedate=5 April 2012 |archiveurl=https://web.archive.org/web/20120405235441/http://www.israel21c.org/health/biolinerx-israel-s-biotech-supermarket }}
3. ^{{cite news|last=Habib-Valdhorn|first=Shiri|title=BiolineRX earns $10m milestone payment|url=http://www.globes.co.il/serveen/globes/docview.asp?did=1000555803&fid=1725|archive-url=https://archive.today/20120803014242/http://www.globes.co.il/serveen/globes/docview.asp?did=1000555803&fid=1725|dead-url=yes|archive-date=3 August 2012|accessdate=28 November 2011|newspaper=Globes|date=28 April 2010}}
4. ^{{cite news|last=Weinreb|first=Gali|title=BiolineRX and Cypress cancel schizophrenia drug agreement|url=http://www.globes.co.il/serveen/globes/docview.asp?did=1000644520&fid=1725|accessdate=28 November 2011|newspaper=Globes|date=11 May 2011|deadurl=yes|archiveurl=https://web.archive.org/web/20110615064401/http://www.globes.co.il/serveen/globes/docview.asp?did=1000644520&fid=1725|archivedate=15 June 2011|df=}}
5. ^{{cite news|title=BioLineRx In-Licenses Novel Compound for Treatment of Neuropathic Pain|url=http://www.biolinerx.com/default.asp?pageid=16&itemid=284|deadurl=yes|archiveurl=https://web.archive.org/web/20150926232047/http://www.biolinerx.com/default.asp?pageid=16&itemid=284|archivedate=2015-09-26|df=}}
6. ^{{cite news|title=Israeli co to hold clinical trial for treatment of Schizophrenia in India|url=http://www.thehindubusinessline.com/industry-and-economy/economy/article2655585.ece?homepage=true&ref=wl_home|accessdate=28 November 2011|newspaper=The Hindu Business Line|date=24 November 2011|location=Jerusalem}}
7. ^{{cite press release |title=BioLineRx Announces Positive Preliminary Results from Phase I Clinical Trial of BL-1021 for Neuropathic Pain |url=http://www.businesswire.com/news/home/20110913006058/en/BioLineRx-Announces-Positive-Preliminary-Results-Phase-Clinical |accessdate=28 November 2011 |via=Business Wire |date=13 September 2011 |location=Jerusalem |author=BioLineRx }}
8. ^{{cite news|title=Bioline looks to heart attack treatment clinical trial|url=http://www.globes.co.il/serveen/globes/docview.asp?did=1000626251&fid=1725|archive-url=https://archive.today/20120803143138/http://www.globes.co.il/serveen/globes/docview.asp?did=1000626251&fid=1725|dead-url=yes|archive-date=3 August 2012|accessdate=28 November 2011|newspaper=Globes|date=27 February 2011}}
9. ^{{cite news|title=US company buys exclusive license for Israeli heart attack drug for $285 million|url=http://www.israel21c.org/briefs/us-company-buys-exclusive-license-for-israeli-heart-attack-drug-for-285-million|accessdate=28 November 2011|newspaper=Israel21c|date=8 July 2009}}
10. ^http://www.biolinerx.com/default.asp?pageid=96&itemid=47
11. ^{{cite news|last=Wrobel|first=Sharon|title=Bioline RX Gets European Device Confirmation for Bl-5010 Drug|url=https://www.bloomberg.com/news/2011-09-15/bioline-rx-gets-european-device-confirmation-for-bl-5010-drug.html|accessdate=28 November 2011|newspaper=Bloomberg|date=15 September 2011}}
12. ^{{cite web|title=BioLineRx has acquired the rights to compound BL-7040 from Yissum and Prof. Soreq|url=http://elsc.huji.ac.il/content/biolinerx-has-acquired-rights-compound-bl-7040-yissum-and-prof-soreq|work=The Hebrew University of Jerusalem|publisher=The Edmond and Lily Safra Center for Brain Sciences|accessdate=28 November 2011|date=27 June 2011}}
13. ^{{cite news|title=BioLineRx signs pact with Genoscience & RFS Pharma to develop and commercialize BL-8030 to treat hepatitis C|url=http://pharmabiz.com/NewsDetails.aspx?aid=67413&sid=2|accessdate=8 February 2012|newspaper=Pharmabiz.com|date=8 February 2012|location=Jerusalem, Israel|deadurl=yes|archiveurl=https://web.archive.org/web/20150221003613/http://pharmabiz.com/NewsDetails.aspx?aid=67413&sid=2|archivedate=21 February 2015|df=}}
14. ^{{cite web |title=BioLineRx—Overview |url=http://www.biolinerx.com/default.asp?pageid=11 |publisher=BioLineRx |accessdate=28 November 2011 |year=2010 |deadurl=yes |archiveurl=https://web.archive.org/web/20110925064030/http://www.biolinerx.com/default.asp?pageid=11 |archivedate=25 September 2011 |df= }}{{self-published inline|certain=y|date=February 2015}}
15. ^{{cite news |last=Grayeff |first=Yigal |title=BioLineRx signs 3 deals to develop drugs |url=http://www.ivc-online.com/ivcWeeklyItem.asp?articleID=2656 |work=Jerusalem Post |via=IVC Research Center |accessdate=28 November 2011 |date=13 January 2005 |deadurl=yes |archivedate=3 February 2010 |archiveurl=https://web.archive.org/web/20100203030129/http://www.ivc-online.com/ivcWeeklyItem.asp?articleID=2656 }}
16. ^{{cite news|last=Cohen|first=Omri|title=Biotech comes of age: Bioline floats at half-billion shekel market cap|url=http://www.haaretz.com/news/biotech-comes-of-age-bioline-floats-at-half-billion-shekel-market-cap-1.212200|accessdate=28 November 2011|newspaper=TheMarker|date=7 February 2007|quote=Bioline Therapeutics today pulled off its initial public offering in Tel Aviv, raising NIS 211 million at a company valuation of NIS 494 million, making this the biggest flotation by a biotechnology company in local history.}}
17. ^{{cite news|last=Rheinheimer|first=Laura|title=BioLineRx raises $50m. in TASE's largest biomedical IPO|url=http://www.jpost.com/Business/Commentary/Article.aspx?id=50790|accessdate=28 November 2011|newspaper=Jerusalem Post|date=8 February 2007|quote=BioLineRx Ltd. on Wednesday priced the largest ever initial public offering of a biomedical company on the Tel Aviv Stock Exchange, raising a total of NIS 211 million, or $50m.}}
18. ^{{cite news |title=BioLineRx ADRs Begin Trading on NASDAQ |url=http://www.highbeam.com/doc/1G1-263702948.html |accessdate=28 November 2011 |via=HighBeam Research |date=13 August 2011 }}{{dead link|date=February 2019|bot=medic}}{{cbignore|bot=medic}}{{citation not found}}
19. ^{{cite news | agency=Reuters | title=BioLineRX ADRs to begin trading on Nasdaq Monday | last=Cohen | first=Tova | editor-last=Magnowski | editor-first=Daniel | date=24 July 2011 | url=https://www.reuters.com/article/2011/07/24/biolinerx-adr-idUSLDE76N01720110724 }}
20. ^{{cite news |url=http://www.businessweek.com/news/2012-01-24/achillion-biolinerx-j-j-snack-rubicon-u-s-equity-movers.html |title=Achillion, BioLineRx, J&J Snack, Rubicon: U.S. Equity Movers |last=Wang |first=Lu |date=24 January 2012 |agency=Bloomberg News |deadurl=yes |archivedate=24 January 2012 |archiveurl=https://web.archive.org/web/20120124181829/http://www.businessweek.com/news/2012-01-24/achillion-biolinerx-j-j-snack-rubicon-u-s-equity-movers.html }}
21. ^1 {{cite news | work=Genetic Engineering & Biotechnology News | title=Novartis Makes $10M Investment in BioLineRx | date=16 December 2014 | volume=35 | issue=2 | page=9 | department=Industry Watch | url=http://www.genengnews.com/gen-news-highlights/novartis-makes-10m-investment-in-biolinerx/81250706/ }}
22. ^{{cite web |url=https://www.bloomberg.com/research/stocks/people/person.asp?personId=8011457 | title=Kinneret Livnat Savitsky Ph.D.: Executive Profile & Biography | accessdate=21 February 2015 |publisher=Bloomberg Business }}
23. ^https://www.bloomberg.com/research/stocks/people/person.asp?personId=25359294&privcapId=5015080

External links

  • BioJerusalem
  • [https://web.archive.org/web/20111003051153/http://www.jda.gov.il/Front/ShowCategory.aspx?CatId=112 Jerusalem Development Authority]
  • [https://web.archive.org/web/20111120031902/http://www.moit.gov.il/CmsTamat/Rsrc/MadaanEnglish/MadaanEnglish.html Office of the Chief Scientist of Israel]
{{Israel NASDAQ}}

7 : Companies listed on TASE|Biotechnology companies established in 2003|Biotechnology companies of Israel|Biotechnology companies|Companies listed on NASDAQ|Drug discovery companies|2003 establishments in Israel
随便看

　

开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。

　

Copyright © 2023 OENC.NET All Rights Reserved
京ICP备2021023879号 更新时间：2024/9/24 4:17:44